Updated Q3 2026

M&A Advisor in Boston: Sell-Side Guide for Founders in 2026

Hiring an M&A advisor in Boston means picking a banker who can speak the language of Kendall Square biotech, Route 128 enterprise software, and the family-run industrial businesses that still line the South Shore. The Boston lower-middle-market is one of the deepest LMM ecosystems in the United States, but it is also crowded, sector-specialized, and dominated by buyers who expect institutional-quality diligence from day one. If you are a founder in Cambridge, the Seaport, Waltham, Burlington, or Worcester thinking about a sale in the next 18 months, this guide is for you.

What does an M&A advisor in Boston actually do?

An M&A advisor in Boston runs a competitive sell-side process for a founder, from valuation and CIM preparation through buyer outreach, LOI negotiation, diligence coordination, and closing. In the Boston market that usually means running targeted processes to a defined pool of local PE firms, strategic acquirers in life sciences or software, and family offices, rather than the broad auctions typical in less specialized metros.

A Boston M&A advisor does five things well. First, they build a defensible valuation using local comparable transactions, which in a metro this sector-heavy means pulling comps that actually match your vertical. Second, they write the confidential information memorandum (CIM) and management presentation in a way that speaks to the specific buyer archetypes active locally. Third, they run a controlled outreach process, typically to 40 to 120 buyers depending on deal size. Fourth, they manage LOI negotiations and select the winning bidder. Fifth, they quarterback diligence and closing alongside your legal and QoE teams.

In the Boston market, the best advisors also do two things that generalist bankers elsewhere often skip. They pre-clear regulatory and IP diligence issues (especially for biotech and medtech deals where FDA and USPTO exposure can kill a process), and they map your buyer universe against the specific PE funds actually deploying Boston-focused capital in the current vintage.

Which M&A advisors serve Boston LMM sellers?

Three local boutiques dominate Boston LMM sell-side mandates: Capstone Partners, Mirus Capital Advisors, and the Boston office of William Blair. Beyond those three, Canaccord Genuity, Solomon Partners, and Signal Hill also run credible LMM processes in the metro, particularly in tech and healthcare.

Capstone Partners is headquartered in Boston and, as a subsidiary of Huntington Bancshares, has more than 175 professionals across 12 industry groups. Capstone acquired TM Capital in December 2025 and launched a Buy-Side M&A Advisory Group the same quarter, which materially deepened its LMM sell-side coverage. Their website (capstonepartners.com) lists industry teams that map cleanly to Boston verticals: industrials, healthcare, business services, technology, and consumer.

Mirus Capital Advisors, based in Burlington, has 38 years of history and has closed more than 300 transactions. Mirus focuses squarely on the $10 million to $100 million enterprise-value LMM band as a generalist, which makes them one of the most common shortlist picks for owner-operators across the Boston metro.

William Blair, though headquartered in Chicago, runs one of the busiest Boston offices in the LMM through mid-cap band. The Boston team focuses on technology and healthcare, and its bench regularly runs sell-side processes for founder-owned software and life sciences companies.

Canaccord Genuity, Solomon Partners, and Signal Hill all maintain Boston offices with LMM sell-side capacity. Signal Hill in particular has a strong Boston tech track record. For a wider view of who else operates in the region, see the firm list on our Massachusetts M&A advisor page.

Boston LMM M&A advisor shortlist

Firm	HQ or Office	Sweet spot	Sector emphasis
Capstone Partners	Boston HQ	$10M to $500M EV	Industrials, healthcare, tech, business services
Mirus Capital Advisors	Burlington HQ	$10M to $100M EV	Generalist LMM
William Blair (Boston)	Chicago HQ, Boston office	$50M to $500M EV	Tech, healthcare
Canaccord Genuity (Boston)	Toronto HQ, Boston office	$25M to $300M EV	Tech, healthcare, life sciences
Solomon Partners (Boston)	New York HQ, Boston office	$50M to $500M EV	Generalist LMM to mid-cap
Signal Hill (Boston)	Baltimore HQ, Boston office	$25M to $250M EV	Enterprise software, tech-enabled services

At CT Acquisitions we talk to Boston founders almost every week who default to whichever banker their attorney recommended. That is not always wrong, but in a metro this sector-specialized, banker fit matters more than banker familiarity. A generalist who has never sold a life sciences business to Berkshire or Advent will leave real money on the table against a specialist who has done it four times.

How do Boston fees compare to national LMM benchmarks?

Boston LMM sell-side fees track national LMM benchmarks closely: retainers of $25,000 to $75,000, success fees of 3 to 6 percent of enterprise value on deals from $10 million to $50 million, and modified Lehman scales on larger deals. Fees compress toward 1.5 to 3 percent as enterprise value crosses $100 million.

Most Boston bankers charge a monthly work fee (retainer) that is credited against the success fee at closing. On a $20 million enterprise-value deal, expect a 4 to 5 percent success fee with a small monthly retainer. On a $75 million deal, expect 2.5 to 3.5 percent. On a $200 million deal, expect a modified Lehman scale that blends down to roughly 1.5 to 2 percent overall.

According to the Axial 2025 State of the Lower Middle Market and the PitchBook Q4 2025 US PE Breakdown, LMM sell-side fees in tech-heavy metros like Boston and San Francisco tend to price 25 to 50 basis points higher than the national median on smaller deals, reflecting the additional diligence complexity and the higher-touch buyer outreach required for specialized verticals.

Typical Boston LMM sell-side fee structure

Enterprise value	Retainer (monthly)	Success fee	Typical minimum fee
$5M to $15M	$10K to $25K	5% to 6%	$400K to $600K
$15M to $50M	$15K to $40K	3.5% to 5%	$750K to $1.25M
$50M to $150M	$25K to $75K	2.5% to 4% (modified Lehman)	$1.5M to $2.5M
$150M+	$50K to $100K	1.5% to 3% blended	$3M+

Success-fee escalators (a higher percentage on dollars above a threshold value) are increasingly common in Boston mandates, particularly for founders who believe their business is undervalued in the market. Ask any banker on your shortlist to model the fee under two scenarios: the base valuation and a stretch valuation. If they resist, that tells you something.

What EBITDA multiples are Boston businesses selling for in 2026?

Boston LMM multiples in 2026 are running above national medians in life sciences, biotech, and enterprise software, and roughly in line with national medians for industrials and business services. Life sciences and biotech LMM deals cleared 10x to 15x plus EBITDA in 2025 processes, and enterprise software cleared 12x to 18x on an ARR-adjusted basis.

The GF Data Q4 2025 report showed a national LMM median of approximately 7.4x TTM EBITDA across all sectors. Boston clears well above that in its sector strongholds. For a founder-owned biotech services business with $8 million EBITDA, credible Boston processes in 2025 landed in the 11x to 14x range. For an $8 million ARR enterprise SaaS business with mid-teens growth, credible Boston processes cleared 4.5x to 6x revenue.

Non-tech, non-life-sciences deals price closer to national medians. A South Shore industrial services business at $6 million EBITDA is a 6.5x to 8x deal, not a 12x deal. A Route 3 HVAC roll-up target at $4 million EBITDA is a 6x to 7.5x deal. The lesson: what pushes Boston multiples above national medians is the presence of specialist buyers who will pay strategic premiums, not the ZIP code itself.

Boston LMM multiples by vertical, 2025 processes

Vertical	Typical multiple	National LMM median (GF Data 2025)	Boston premium
Life sciences and biotech services	10x to 15x+ EBITDA	7.4x	+35% to +100%
Enterprise software and SaaS	12x to 18x ARR-adjusted	8x to 10x ARR	+30% to +80%
Healthcare services	8x to 12x EBITDA	7.4x	+10% to +60%
Financial services	8x to 11x EBITDA	7.4x	+10% to +50%
Industrial services	6.5x to 8x EBITDA	7.4x	Flat to +10%
Consumer and retail	5.5x to 7.5x EBITDA	6.5x	Flat to +15%

Which PE firms have offices in Boston?

Boston is home to one of the deepest local PE ecosystems in the United States. Bain Capital, Advent International, Berkshire Partners, Summit Partners, and TA Associates are all headquartered in the metro, alongside Great Hill Partners, Audax Group, Charlesbank Capital Partners, Spectrum Equity, and Riverside Partners.

Bain Capital (Boston HQ) is a global mega-cap PE firm and one of the largest alternative asset managers in the world. Bain runs multiple strategies (private equity, credit, venture, real estate, life sciences) and is an active LMM buyer through its middle-market and life sciences funds.

Advent International (Boston HQ) is a global PE firm with a strong healthcare and business services franchise. Advent is more mid-cap than LMM but regularly acquires LMM platforms as add-ons.

Berkshire Partners (Boston HQ) focuses on mid-cap deals and is a frequent buyer of Boston-area founder-owned businesses in consumer, industrials, healthcare, and business services.

Summit Partners and TA Associates are both Boston-headquartered growth equity firms with deep track records in software, healthcare, and financial services. Both are active in the LMM through their growth funds and are common bidders on Boston SaaS processes.

Additional PE firms with meaningful Boston presence and active LMM programs include Great Hill Partners, Audax Group, Charlesbank Capital Partners, Spectrum Equity, and Riverside Partners. According to the PitchBook Q4 2025 US PE Breakdown, Boston-headquartered funds collectively deployed more than $85 billion in 2025, a meaningful share of which flowed into LMM add-on activity.

What are the dominant Boston M&A verticals in 2026?

The dominant Boston M&A verticals in 2026 are life sciences and biotech, medtech, healthcare services, enterprise software and SaaS, robotics, financial services (Fidelity and State Street ecosystems), and higher-education-adjacent businesses. These sectors account for the majority of disclosed LMM transactions in the metro.

Boston’s identity as a life sciences capital is not marketing. The MassBio 2025 Industry Snapshot reports more than 1,100 life sciences companies in Massachusetts, most concentrated in Cambridge, the Seaport, and along Route 128. That density creates a real LMM M&A market for CROs, CDMOs, lab services, biomanufacturing, and clinical-trial services businesses. Multiples in this vertical routinely clear 10x EBITDA and higher.

Enterprise software is the second pillar. Route 128 and the Seaport host thousands of B2B SaaS and vertical SaaS businesses, and the Boston tech ecosystem now rivals New York for LMM software deal count. Growth equity buyers (Summit, TA, Spectrum, Great Hill) plus generalist PE firms create real bidding depth at the $8 million to $25 million ARR band.

Financial services M&A is anchored by the Fidelity and State Street ecosystems, plus the deep bench of RIAs, wealth managers, and fintech-adjacent businesses in the metro. Boston is one of the top-3 US metros for RIA M&A activity by deal count.

Healthcare services M&A (dental, dermatology, urgent care, behavioral health, physical therapy, home health) tracks national LMM volumes but with an above-median density of specialist buyers thanks to the concentration of healthcare-focused PE in the metro.

Which local law firms and accounting practices handle Boston sell-side deals?

Ropes & Gray, Goodwin Procter, and WilmerHale are the three Boston-headquartered law firms most often on the sell-side of LMM deals in the metro, particularly for life sciences, tech, and PE-backed processes. On the accounting side, BDO Boston and CBIZ Tofias lead LMM QoE and tax work, with all four Big 4 firms maintaining large Boston offices.

Ropes & Gray (Boston HQ) is a global law firm with a market-leading PE and life sciences M&A practice. Ropes represents both PE sponsors and founder sellers, and its Boston partners have handled a large share of the biotech and pharma services deals that priced above 10x in 2025.

Goodwin Procter (Boston HQ) has one of the deepest tech, life sciences, and PE M&A benches in the country. For founder-owned software and biotech companies looking for sell-side counsel, Goodwin is on nearly every shortlist.

WilmerHale (Boston HQ) rounds out the top three, with a particularly strong tech and life sciences M&A practice and deep ties into the venture-backed startup ecosystem that feeds LMM sell-side deal flow.

On the accounting side, BDO Boston and CBIZ Tofias are the LMM specialists most often engaged for sell-side quality-of-earnings (QoE) reports, tax structuring, and working-capital analyses. The Big 4 (Deloitte, EY, KPMG, PwC) all maintain major Boston offices and pick up the mid-cap end of the market. According to the AICPA and industry-wide 2025 QoE fee data, sell-side QoE engagements in the Boston metro typically run $60,000 to $150,000 for LMM deals, with tax structuring adding another $25,000 to $75,000.

How does selling in Boston differ from selling elsewhere in Massachusetts?

Selling in Boston differs from selling elsewhere in Massachusetts in three ways: buyer depth is dramatically higher, sector specialization matters more, and process cadence tends to be faster. A founder in Springfield or Pittsfield will get fewer bids from fewer sponsors, but often with less due diligence overhead, than a comparable business in Cambridge or the Seaport.

The buyer-depth gap is real. A Boston-metro business with $6 million EBITDA in a target vertical (biotech services, SaaS, healthcare services) can credibly attract 50 to 90 bids in a well-run process. That same business in Western Massachusetts might attract 20 to 40 bids, and the sector premium disappears. That is not a failure of the outside-Boston market; it is a reflection of where the specialist buyers physically sit.

Sector specialization also matters more inside the metro. In Boston, buyers expect deep vertical knowledge from your CIM and management team. Outside the metro, generalist buyers dominate, and a well-run generalist process wins. This changes which banker you should hire.

Process cadence is faster in Boston. Well-run Boston processes typically go from banker engagement to close in 5 to 7 months. Statewide, the same process usually runs 6 to 9 months. For more on the statewide picture, see our Massachusetts M&A advisor overview.

What questions should you ask a Boston M&A advisor?

Before you sign an engagement letter with an M&A advisor in Boston, ask about their five most recent closed transactions in your vertical, the specific PE and strategic buyers they will approach, their fee structure under two valuation scenarios, and how they handle diligence for regulated verticals like life sciences or healthcare services.

Ten questions to ask every Boston banker on your shortlist:

1. What are your five most recent closed sell-side transactions in my vertical, and what were the multiples?
2. Which PE firms and strategics do you plan to approach, and which of those have you closed with in the last 24 months?
3. What is your fee structure at the base valuation and at a stretch valuation 25 percent higher?
4. Who on your team will personally run my process, day to day?
5. How do you handle sell-side QoE coordination, and which Boston QoE providers do you recommend?
6. What is your realistic timeline from engagement to LOI to close?
7. How do you handle competing bids and go-shop provisions in a Boston process?
8. What is your approach to regulatory diligence (FDA, USPTO, state healthcare regulators) in my vertical?
9. How do you get paid if I take a strategic bid from a party I already know?
10. What is your tail period, and how do you define a covered transaction?

The answer to question 2 tells you almost everything. If the banker cannot name six to ten specific Boston PE firms they will approach, with rationale for each, they do not know your market well enough to run your process. That is the single fastest way to filter your shortlist.

Related CT Acquisitions guides

These companion guides cover the sell-side process end to end. Read alongside this page for the full picture on fees, timelines, and buyer archetypes.

• M&A Advisory Pillar Guide (2026)
• Buy-Side M&A Advisory
• Lower Middle Market M&A Advisor
• Business Appraisal Cost 2026
• Investment Bank Fees LMM 2026
• Quality of Earnings (QoE) Guide
• M&A Advisor for HVAC Business
• M&A Advisor for Plumbing Business
• M&A Advisor for Orthopedic Practice

Frequently asked questions

How long does a Boston LMM sell-side process take?

Typical Boston LMM processes run 5 to 7 months from engagement to close: 4 to 6 weeks of prep and CIM drafting, 4 to 6 weeks of buyer outreach and management meetings, 3 to 5 weeks from LOI to signed exclusivity, and 8 to 12 weeks of confirmatory diligence and closing. Life sciences deals with FDA touchpoints usually add 4 to 8 weeks.

What is the minimum EBITDA to hire a top Boston M&A advisor?

Most top Boston bankers have a $1.5 million to $2 million EBITDA floor for sell-side mandates, which typically translates to a $10 million to $15 million enterprise value floor. Mirus Capital Advisors and other LMM specialists work down to smaller deals; bulge-bracket and mid-cap Boston offices generally do not.

Should I hire a Boston boutique or a national bank’s Boston office?

For deals below $50 million enterprise value, a Boston boutique like Capstone Partners or Mirus Capital Advisors will usually give you better attention and more senior-banker time on the deal. For deals above $75 million with strategic buyers in play, a national bank’s Boston office (William Blair, Canaccord Genuity, Solomon Partners) brings a deeper buyer network and better cross-border access.

What are the biggest deal-killers in Boston LMM processes?

The three most common deal-killers we see in Boston LMM processes are: unresolved IP or regulatory issues (especially for biotech and medtech), quality-of-earnings surprises during confirmatory diligence, and unrealistic seller earn-out expectations. All three are avoidable with proper pre-marketing preparation.

Do Boston buyers typically pay all-cash or roll equity?

For LMM deals below $30 million, Boston PE buyers commonly ask for 15 to 25 percent seller rollover equity as a way to align incentives. For deals above $50 million, all-cash offers are more common but often paired with earn-outs. Strategic buyers (life sciences and software) more often pay all-cash for LMM tuck-in acquisitions.

What is the tax exposure for a Boston founder selling for $20 million?

A Massachusetts founder selling C-corp stock for $20 million faces a blended federal capital gains rate of 23.8 percent (20 percent plus 3.8 percent NIIT), plus Massachusetts income tax of 5 percent on qualifying gains and 9 percent on income above $1 million under the 2023 millionaire’s tax. Structuring (QSBS Section 1202, installment sales, F-reorganizations) can materially reduce this. Always consult a Boston tax advisor before signing an LOI. See IRS Topic No. 409 and the Massachusetts Department of Revenue.

How does the Boston LMM compare to New York or San Francisco?

Boston sits in the top-8 US LMM metros by deal count and top-3 for life sciences and biotech LMM deals specifically. New York has more generalist PE buyers and more financial services deal flow; San Francisco has more late-stage venture and tech deal flow. Boston is deeper than either in life sciences and roughly comparable in tech, per the PitchBook Q4 2025 US PE Breakdown and the PitchBook 2025 US VC Valuations Report.

What accounting standard do most Boston LMM sellers use for QoE?

Most Boston LMM sell-side QoE reports are prepared using US GAAP with common non-GAAP adjustments (add-backs for owner compensation, discretionary expenses, one-time items). BDO Boston and CBIZ Tofias both follow the AICPA guidance on QoE engagements. For life sciences deals, expect additional revenue-recognition scrutiny under ASC 606, particularly for milestone-based contracts.